Exploring the multifaceted characteristics of aura in migraine: A multicenter, cross-sectional study.

Autor: Dalla Volta G; U.O. Neurologia, Istituto Clinico 'Città di Brescia', Brescia, Italy., Russo A; Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy., Silvestro M; Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy., Ornello R; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Caponnetto V; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Sacco S; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Zavarise P; U.O. Neurologia, Istituto Clinico 'Città di Brescia', Brescia, Italy., Cortinovis M; U.O. Neurologia, Istituto Clinico 'Città di Brescia', Brescia, Italy., Lo Castro F; Department of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy., Guerzoni S; Department of Specialist Medicines, Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse, Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy., Prudenzano MP; Headache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy., Gentile M; Headache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, Italy., De Icco R; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.; Headache Science & Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy., Vaghi G; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.; Headache Science & Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy., Tassorelli C; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.; Headache Science & Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy., De Tommaso M; Neurophysiopathology Unit, DiBrain Department, University of Bari Aldo Moro, Bari, Italy., Scannicchio S; Neurophysiopathology Unit, DiBrain Department, University of Bari Aldo Moro, Bari, Italy., Rainero I; Headache Center, Department of Neuroscience 'Rita Levi Montalcini', University of Torino, Turin, Italy., Granato A; Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste, Trieste, Italy., Sepe FN; Neurology Department, Azienda Ospedaliero Universitaria, Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Ferrandi D; Neurology Department, Azienda Ospedaliero Universitaria, Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Rebecchi V; Headache Center, UO Neurologia and Stroke Unit, ASST -Pavia, Voghera, Italy., Alessandri M; UOC Medicina Interna, Sant'Andrea Hospital, Massa Marittima, USL Toscana Sud-est, Massa Marittima, Italy., Burgalassi A; Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy.; Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy., Romozzi M; Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy., Casalena A; Neurology Unit, 'G. Mazzini' Hospital, Teramo, Italy., Chiarugi A; Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence, Italy.; Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy., Geppetti P; Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.; Department of Pathobiology, School of Dentistry, New York University, New York, NY, USA., Iannone LF; Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Jazyk: angličtina
Zdroj: Cephalalgia : an international journal of headache [Cephalalgia] 2024 Nov; Vol. 44 (11), pp. 3331024241299453.
DOI: 10.1177/03331024241299453
Abstrakt: Background: Migraine with aura (MwA) is a debilitating disorder characterized by paroxysmal attacks of pain preceded or accompanied by reversible neurological symptoms. While the pathophysiology remains unclear, trigeminovascular system activation and cortical spreading depression have been implicated. This study aims to comprehensively investigate and characterize the diverse clinical features and manifestations of aura, as well as the types of acute medications self-administered for aura management.
Methods: A multicenter, cross-sectional study was conducted using data from the Italian Headache Registry (RICe). Aura characteristics, frequency, duration and associated migraine premonitory symptoms were collected. Acute medication use and timing (headache or aura phase) were assessed.
Results: The study included 272 patients with a diagnosis of MwA. Most patients (99.3%) experienced typical aura symptoms, with visual aura (96.3%) being the most prevalent, followed by sensory (33.0%) and speech and/or language aura (25.6%). Brainstem aura (8.5%) and motor aura (1.8%) were less common. Notably, 13.0% of patients reported aura relapses within 24 hours. Triptans (39.7%), non-steroidal anti-inflammatory drugs (47.8%) and nutraceuticals (59.9%) were commonly used for acute aura management.
Conclusions: This study reports several different aura manifestations, highlighting atypical features, aura relapse rates and treatment approaches for aura. These findings could contribute to a deeper understanding of aura and its management in clinical settings.
Competing Interests: Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: PG received personal fees from Allergan, Eli Lilly, Novartis, Amgen and TEVA; grants from Amgen, TEVA, Eli-Lilly, Allergan and Chiesi; is on the Scientific Advisory Board for Endosome Therapeutics; and is a founding scientist of FloNext srl, Spinoff of the University of Florence. FDC received personal fees from TEVA, Eli Lilly and Novartis. LFI received personal fees from Eli-Lilly and TEVA, and a travel grant from Lundbeck. SS reports personal fees as a speaker or advisor from Abbott, Allergan-AbbVie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Pfizer and Teva, and research grants from Novartis. RO reports personal fees from Novartis, Eli Lilly and Teva, and non-financial support from Novartis, Allergan, Eli Lilly and Teva. SG received personal fees from Allergan/AbbVie, Eli Lilly, Novartis, Teva and Lundbeck. Grazia Sances received personal fees as a speaker or was on the Advisory Board for Eli-Lilly, Novartis, TEVA, Lundbeck and Pfizer. RDI received speaker honoraria and advisory board participation: Eli-Lilly, TEVA, Lundbeck, Pfizer, AbbVie; MPP received speaker honoraria and advisory board participation from Abbvie, Idorsia, Eli-Lilly, Novartis, Pfizer, TEVA. The other authors have no conflicting interests.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje